ArticleJID innovations : skin science from molecules to population health2026
Diabetes status is associated with greater disease severity in hidradenitis suppurativa.
Article in JID innovations : skin science from molecules to population health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the rising prevalence of endocrine conditions in the U.S., it is important to examine the relationship between diabetes mellitus and hidradenitis suppurativa (HS) severity. This retrospective, cross-sectional study evaluated whether diabetes status and HbA1c levels are associated with HS severity among 275 physician-diagnosed patients seen at an HS Specialty Clinic between June 2016 and January 2021. The primary outcome was HS severity measured by the International HS Severity Score System (IHS4); the secondary outcome was pain severity measured by the Numeric Pain Rating Scale (NRS).Among participants, 44.3% were non-diabetic, 35.3% pre-diabetic, and 20.4% diabetic. Median HbA1c levels were lowest in non-diabetic patients (5.3 [5.1, 5.5]) and highest in diabetic patients (6.9 [6.3, 8.4]). The NRS pain score was also highest in the diabetic cohort (5.0 [0.0-8.0]) compared to the non-diabetic (2.0 [0.0-5.0]) and pre-diabetic (4.0 [0.0-6.0]) groups (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.